Compass Therapeutics, Inc. (NASDAQ: CMPX)

Compass Therapeutics Inc is a clinical stage oncology focused biopharmaceutical company developing proprietary antibody based therapeutics to treat multiple human diseases. Its scientific focus centers on the interplay between angiogenesis the immune system and tumor growth to design product candidates that modulate the microvasculature activate effector immune cells and alleviate tumor immunosuppressive mechanisms.

Compass Therapeutics generates revenue primarily through upfront payments milestone payments and royalty receipts from licensing agreements with partners such as ABL Bio and Adimab. The company may also earn revenue from future commercial sales of its product candidates upon receiving regulatory approval.

Compass Therapeutics operates in the highly competitive immuno oncology and angiogenesis therapeutic sectors where it faces large established pharmaceutical companies such as Merck Bristol Myers Squibb Roche AstraZeneca and Pfizer. The company differentiates itself through its proprietary StitchMabs platform which enables the creation of bispecific antibodies that simultaneously engage two distinct biological targets. Early clinical data showing activity in biliary tract cancer colorectal cancer and other solid tumors together with a growing intellectual property portfolio provide additional competitive advantages.

The company serves oncology patients receiving treatment in hospitals clinics and other healthcare settings. Its licensing partners include ABL Bio and Adimab which collaborate on the development and commercialization of specific product candidates.